DrugPatentWatch Database Preview
ASTELLAS Company Profile
» See Plans and Pricing
What is the competitive landscape for ASTELLAS, and what generic alternatives to ASTELLAS drugs are available?
ASTELLAS has thirty-five approved drugs.
There are twelve US patents protecting ASTELLAS drugs. There is one tentative approval on ASTELLAS drugs.
There are three hundred and three patent family members on ASTELLAS drugs in forty countries and sixty-three supplementary protection certificates in eighteen countries.
Summary for ASTELLAS
| International Patents: | 303 |
| US Patents: | 12 |
| Tradenames: | 19 |
| Ingredients: | 14 |
| NDAs: | 35 |
Drugs and US Patents for ASTELLAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | VESICARE LS | solifenacin succinate | SUSPENSION;ORAL | 209529-001 | May 26, 2020 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | |||||
| Astellas | AMBISOME | amphotericin b | INJECTABLE, LIPOSOMAL;INJECTION | 050740-001 | Aug 11, 1997 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | |||||
| Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-001 | Mar 6, 2015 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | |||||
| Astellas | CRESEMBA | isavuconazonium sulfate | CAPSULE;ORAL | 207500-001 | Mar 6, 2015 | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | |||||
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | AP | RX | Yes | Yes | Get Started for $10 | Get Started for $10 | ||||
| Astellas | PROGRAF | tacrolimus | CAPSULE;ORAL | 050708-003 | Aug 24, 1998 | AB | RX | Yes | No | Get Started for $10 | Get Started for $10 | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ASTELLAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-002 | Mar 16, 2005 | 5,376,634 | Get Started for $10 |
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,655,637 | Get Started for $10 |
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 7,144,872 | Get Started for $10 |
| Astellas | MYCAMINE | micafungin sodium | INJECTABLE;INTRAVENOUS | 021506-003 | Jun 27, 2006 | 6,265,536 | Get Started for $10 |
| Astellas | ASTAGRAF XL | tacrolimus | CAPSULE, EXTENDED RELEASE;ORAL | 204096-002 | Jul 19, 2013 | 6,884,433 | Get Started for $10 |
| Astellas | LEXISCAN | regadenoson | SOLUTION;INTRAVENOUS | 022161-001 | Apr 10, 2008 | 8,106,029 | Get Started for $10 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ASTELLAS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 40 mg | ➤ Subscribe | 2016-08-31 |
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-18 |
| ➤ Subscribe | Injection | 0.08 mg/mL, 5 mL vial | ➤ Subscribe | 2012-04-10 |
| ➤ Subscribe | Extended-release Capsules | 0.5 mg, 1 mg, and 5 mg | ➤ Subscribe | 2013-11-15 |
| ➤ Subscribe | For Injection | 50 mg/vial and 100 mg/vial | ➤ Subscribe | 2014-06-16 |
| ➤ Subscribe | Injection | 3 mg/mL, 20 mL and 30 mL vials | ➤ Subscribe | 2005-04-16 |
| ➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2009-04-08 |
International Patents for ASTELLAS Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Lithuania | 2572717 | Get Started for $10 |
| South Korea | 20080014039 | Get Started for $10 |
| Indonesia | 29468 | Get Started for $10 |
| Norway | 2020001 | Get Started for $10 |
| South Africa | 201208762 | Get Started for $10 |
| Japan | 4727880 | Get Started for $10 |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ASTELLAS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1893196 | 491 | Finland | Get Started for $10 | |
| 1189916 | 11C0004 | France | Get Started for $10 | PRODUCT NAME: REGADENOSON ET SES SELS; REGISTRATION NO/DATE: EU/1/10/643/001 20100906 |
| 1189916 | CA 2011 00005 | Denmark | Get Started for $10 | PRODUCT NAME: REGADENOSON OG SALTE DERAF |
| 2428508 | CA 2020 00006 | Denmark | Get Started for $10 | PRODUCT NAME: GILTERITINIB ELLER ET SALT DERAF; REG. NO/DATE: EU/1/19/1399 20191028 |
| 1189916 | 392 | Finland | Get Started for $10 | |
| 2428508 | 20C1003 | France | Get Started for $10 | PRODUCT NAME: GILTERITINIB OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/19/1399 20191028 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
